Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.
Weaver’s pre-transaction due diligence services helped a multinational real estate corporation move forward with confidence on a global acquisition.
Weaver helps a health system evaluate its revenue quality, estimate collections and gain clarity on complex streams.
Weaver’s transaction advisory team highlights a recent success guiding a client through a contentious net working capital and earn-out dispute.
Weaver supported an aviation management firm with sell-side financial and tax assistance, saving the client over $1 million in post-close adjustments.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Weaver’s Transaction Advisory Services team highlights a recent success story, guiding a client through an investment in a fast-casual restaurant.
Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.
When a small to medium-sized business owner exits a company, the factors they need to ponder are varied and complex. Here’s an overview of those considerations.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.
1 2 3 4 10